SCHEMBL16396158

SCHEMBL16396158

CCOC(=O)c1cc2cc(NS(C)(=O)=O)ccc2s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.58
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
MMP2 P08253 1/20 0.57
MMP13 P45452 1/20 0.57
HPGD P15428 3/20 0.56
RECQL P46063 1/20 0.56
PTPN2 P17706 2/20 0.46
ALDH1A1 P00352 1/20 0.44
MAPK1 P28482 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
AR P10275 2/20 0.43
ERBB2 P04626 1/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
AURKA O14965 1/20 0.41
AURKB Q96GD4 1/20 0.41
GAA P10253 1/20 0.40
POLB P06746 1/20 0.40
HDAC1 Q13547 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15698912 0.87 MEN1 (0.70) MAPTMEN1KMT2AMMP2MMP13
SCHEMBL3981939 0.82 MEN1 (0.67) MAPTMEN1KMT2AALDH1A1HDAC6
SCHEMBL1883726 0.82 MEN1 (0.64) MAPTMEN1KMT2AHPGDALDH1A1
SCHEMBL15697598 0.81 MEN1 (0.55) MAPTMEN1KMT2AMMP13HDAC6
SCHEMBL13845652 0.81 MAPT (0.66) MAPTMEN1KMT2AALDH1A1AR
SCHEMBL16396150 0.80 MEN1 (0.51) MAPTMEN1KMT2AMMP2MMP13
SCHEMBL6507545 0.80 HDAC1 (0.60) MAPTMEN1KMT2AHDAC6HDAC1
SCHEMBL26605120 0.80 MAPT (0.51) MAPTMEN1KMT2AHPGDPTPN2
SCHEMBL18264030 0.79 PTPN2 (0.49) MAPTMEN1KMT2AHPGDPTPN2
SCHEMBL1205380 0.78 PTPN2 (0.51) MAPTMEN1KMT2AHPGDPTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10562912-B2 Heterocyclic derivatives and use thereof C&C RESEARCH LABORATORIES (KR) 2020-02-18 US disclosed
EP-3004057-B1 HETEROCYCLIC DERIVATIVES AND THEIR USE AS STAT 3 INHIBITORS C&C RES LAB (KR) 2018-07-25 EP disclosed
US-20160108056-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF C&C RESEARCH LABORATORIES (KR) 2016-04-21 US disclosed
EP-3004057-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF C&C Research Laboratories (KR) 2016-04-13 EP disclosed
WO-2014196793-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF C&C RESEARCH LABORATORIES (KR) 2014-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160108056-A1 HETEROCYCLIC DERIVATIVES AND USE THEREOF STAT3, JAK2, STAT5A MAPT 4514/4885MEN1 3206/4885KMT2A 3017/4885
US-10562912-B2 Heterocyclic derivatives and use thereof STAT3, JAK2, STAT5A MAPT 4514/4885MEN1 3206/4885KMT2A 3017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.